

Supporting Information

Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors

Jinbo Zhao,[†] Huiping Zhao,[†] Jessica A. Hall,[†] Douglas Brown,[‡] Eileen Brandes,[§] Joseph Bazzill,[#] Patrick T. Grogan,^{§,||} Chitra Subramanian,[§] George Vielhauer,[‡] Mark S. Cohen,
^{§, #, ||} and Brian S. J. Blagg^{*†}

[†] *Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The
University of Kansas, Lawrence, Kansas 66045, USA*

*Departments of[§] Surgery, [#] Pharmaceutical Chemistry, University of Michigan, Ann
Arbor, MI, 48109, USA*


*Departments of[‡] Urology, || Pharmacology, Toxicology and Therapeutics, The University
of Kansas Medical Center, 3901 Rainbow Blvd., Mail Stop 1016, Kansas City, KS 66160,
USA*

** Author to whom correspondence should be addressed. Phone: (785) 864-2288. Fax:
(785) 864-5326. Email: bblagg@ku.edu*


Chemistry General. The ^1H (500 and 400 MHz) and ^{13}C NMR (125 and 100 MHz) spectra were recorded on 500 and 400 MHz spectrometer. Data are reported as p = pentet, q = quartet, t = triplet, d = doublet, s = singlet, bs = broad singlet, m = multiplet; coupling constant(s) in Hz. High resolution mass spectral data were obtained on a time-of-flight mass spectrometer and analysis was performed using electrospray ionization. TLC was performed on glass backed silica gel plates with spots visualized by UV light. All solvents were reagent grade and, when necessary, were purified and dried by standard methods.

Synthesis and Compound Characterization


General procedure for the synthesis of triazolyl acids **7**.



The triazolyl acids **7** were synthesized according to a literature procedure.¹ To a 100 mL sealed tube was added CuSO_4 (16 mg, 0.1 mmol), sodium ascorbate (40 mg, 0.2 mmol) and H_2O (2 mL). The mixture was then treated with azide (266 mg, 2.0 mmol) and *t*-BuOH (2 mL) and then propiolic acid (168 mg, 2.4 mmol), the tube was sealed and the mixture was stirred overnight. The mixture was then added saturated NaHCO_3 solution, extracted with ether (10 mL \times 2). The organic layer was then discarded, and the aqueous layer was acidified with 1N H_2SO_4 , and extracted with EtOAc (15 mL \times 3) and dried over Na_2SO_4 . The solvent was evaporated to afford the title triazole acid (334 mg, 82% yield) as a white solid which is usually pure enough to be used in the next step. ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1 H), 7.44-7.40 (m, 3 H), 7.34-7.28 (m, 2 H), 5.60 (s, 2 H). HNMR is consistent with the literature.¹




1-(4-Chlorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid (7g): The reaction of 4-chlorobenzyl azide (6.9 mmol, 1.64 g), CuSO_4 (56 mg, 0.35 mmol), sodium ascorbate (140 mg, 0.7 mmol), and propiolic acid (590 mg, 8.4 mmol) in *t*-BuOH (8 mL) and H_2O (8 mL) to afford the title triazole acid (987 mg, 60% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.14 (s, 1 H), 8.79 (s, 1 H), 7.49-7.43 (m, 2 H), 7.40-7.35 (m, 2 H), 5.66 (s, 2 H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 161.6, 139.9, 134.6, 133.0, 130.0, 129.1, 128.8, 52.2; HRMS (TOF-ESI) calcd for $\text{C}_{10}\text{H}_8\text{ClN}_3\text{O}_2\text{Na}[\text{M}+\text{Na}]^+$: 260.0203, found: 260.0200.




1-(4-Bromobenzyl)-1H-1,2,3-triazole-4-carboxylic acid (7h):

The reaction of 4-bromobenzyl azide (5 mmol, 1.06 g), CuSO₄ (40 mg, 0.25 mmol), sodium ascorbate (100 mg, 0.5 mmol), and propiolic acid (420 mg, 6 mmol) in *t*-BuOH (6 mL) and H₂O (6 mL) to afford the title triazole acid (575 mg, 40% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.74 (s, 1 H), 7.61-7.57 (m, 2 H), 7.33-7.28 (m, 2 H), 5.63 (s, 2 H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 161.7, 140.3, 135.0, 131.7, 130.3, 128.9, 121.6, 52.2; HRMS (TOF-ESI) calcd for C₁₀H₈BrN₃O₂Na[M+Na]⁺: 303.9698, found: 303.9705.




1-(4-Methylbenzyl)-1H-1,2,3-triazole-4-carboxylic acid (7i):

The reaction of 4-methylbenzyl azide (636 mg, 4.32 mmol), CuSO₄ (35 mg, 0.22 mmol), sodium ascorbate (86 mg, 0.43 mmol), and propiolic acid (364 mg, 5.2 mmol) in *t*-BuOH (6 mL) and H₂O (6 mL) to afford the title triazole acid (712 mg, 76% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.74 (s, 1 H), 7.25 (d, *J* = 8.0 Hz, 2 H), 7.19 (d, *J* = 8.0 Hz, 2 H), 5.59 (s, 2 H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 161.6, 139.8, 137.6, 132.6, 129.3, 128.9, 128.0, 52.8, 20.7; HRMS (TOF-ESI) calcd for C₁₁H₁₁N₃O₂Na[M+Na]⁺: 240.0749; found: 240.0742.




*1-(4-*t*-Butylbenzyl)-1H-1,2,3-triazole-4-carboxylic acid (7k):*

The reaction of 4-*t*-butylbenzyl azide (4.68 mmol, 886 mg), CuSO₄ (37 mg, 0.23 mmol), sodium ascorbate (93 mg, 0.47 mmol), and propiolic acid (328 mg, 4.68 mmol) in *t*-BuOH (8 mL) and H₂O (8 mL) to afford the title triazole acid (750 mg, 62% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.77 (s, 1 H), 7.43-7.36 (m, 2 H), 7.31-7.25 (m, 2 H), 5.60 (s, 2 H), 1.26 (s, 9 H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 161.6, 150.8, 139.8, 132.7, 128.9, 127.8, 125.6, 52.7, 34.3, 31.0; HRMS (TOF-ESI) calcd for C₁₄H₁₇N₃O₂Na[M+Na]⁺: 282.1218; found: 282.1215.



1-(4-Nitrobenzyl)-1H-1,2,3-triazole-4-carboxylic acid (7l):


The reaction of 4-nitrobenzyl azide (777 mg, 4.36 mmol), CuSO₄ (35 mg, 0.22 mmol), sodium ascorbate (86 mg, 0.436 mmol), and propiolic acid (305 mg, 4.36 mmol) in *t*-BuOH (10 mL) and H₂O (10 mL) to afford the title triazole acid (940 mg, 87% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.18 (s, 1 H), 8.86 (s, 1 H), 8.25 (d, *J* = 8.8 Hz, 2 H), 7.57 (d, *J* = 8.8 Hz, 2 H), 5.84 (s, 2 H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 161.5, 147.3, 142.9, 140.0, 129.5, 129.1, 124.0, 52.1; HRMS (TOF-ESI) calcd for C₁₀H₈N₄O₄Na[M+Na]⁺: 271.0443, found: 277.0436.



1-(3-Chlorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid (7n):


The reaction of 3-chlorobenzyl azide (309 mg, 1.84 mmol), propiolic acid (126 mg, 1.8 mmol), CuSO₄ (15 mg, 0.092 mmol), sodium ascorbate (37 mg, 0.184 mmol) in *t*-BuOH (10 mL) and H₂O (10 mL) afforded the title compound (280 mg, 66% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.14 (bs, 1 H), 8.83 (s, 1 H), 7.49-7.45 (m, 1 H), 7.44-7.40 (m, 2 H), 7.34-

7.27 (m, 1 H), 5.67 (s, 2 H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 161.6, 139.9, 137.9, 133.3, 130.7, 129.2, 128.3, 128.0, 126.8, 52.2; HRMS (TOF-ESI) calcd for $\text{C}_{10}\text{H}_8\text{ClN}_3\text{O}_2\text{Na}[\text{M}+\text{Na}]^+$: 260.0203, found: 260.0210.




1-(3-Methoxybenzyl)-1H-1,2,3-triazole-4-carboxylic acid (7o):

The reaction of 3-methoxybenzyl azide (734 mg, 4.5 mmol), CuSO_4 (36 mg, 0.225 mmol), sodium ascorbate (89 mg, 0.45 mmol), and propiolic acid (280 mg, 4.0 mmol) in *t*-BuOH (10 mL) and H_2O (10 mL) to afford the title triazole acid (690 mg, 74% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 13.12 (s, 1 H), 8.78 (s, 1 H), 7.30 (t, J = 8.0 Hz, 1 H), 6.96-6.87 (s, 3 H), 5.61 (s, 2 H), 3.75 (s, 3 H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 161.6, 159.4, 139.8, 137.0, 130.0, 129.0, 120.1, 113.8, 113.7, 55.1, 52.9; HRMS (TOF-ESI) calcd for $\text{C}_{11}\text{H}_{11}\text{N}_3\text{O}_3\text{Na}[\text{M}+\text{Na}]^+$: 256.0698, found: 256.0694.




1-(2-Chlorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid (7p):

The reaction of 2-chlorobenzyl azide (4.87 mmol, 816 mg), CuSO_4 (40 mg, 0.25 mmol), sodium ascorbate (99 mg, 0.5 mmol), and propiolic acid (420 mg, 6.0 mmol) in *t*-BuOH (8 mL) and H_2O (8 mL) to afford the title triazole acid (817 mg, 71% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 13.15 (bs, 1 H), 8.74 (s, 1 H), 7.56-7.51 (m, 1 H), 7.45-7.35 (m, 2 H), 7.28-7.23 (m, 1 H), 5.77 (s, 2 H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 161.6, 139.7, 132.8, 132.6, 130.5, 130.4, 129.6, 129.5, 127.8, 50.8; HRMS (TOF-ESI) calcd for $\text{C}_{10}\text{H}_8\text{ClN}_3\text{O}_2\text{Na}[\text{M}+\text{Na}]^+$: 260.0203, found: 260.0201.




1-Phenethyl-1H-1,2,3-triazole-4-carboxylic acid (7r):

The reaction of 2-phenylethylazide (721 mg, 4.9 mmol), propiolic acid (274 mg, 3.92 mmol), CuSO_4 (40 mg, 0.25 mmol) and sodium ascorbate (100 mg, 0.50 mmol) in *t*-BuOH/ H_2O (10 mL/10 mL) afforded the title acid (635 mg, 75% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 13.05 (s, 1 H), 8.59 (s, 1 H), 7.32-7.24 (m, 2 H), 7.24-7.15 (m, 3 H), 4.67 (t, J = 7.2 Hz, 2 H), 3.20 (t, J = 7.2 Hz, 2 H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 161.7, 139.4, 137.3, 128.9, 128.7, 128.4, 126.6, 50.6, 35.4; HRMS (TOF-ESI) calcd for $\text{C}_{11}\text{H}_{11}\text{N}_3\text{O}_2\text{Na}[\text{M}+\text{Na}]^+$: 240.0749, found: 240.0746.




1-(3-Phenylpropyl)-1H-1,2,3-triazole-4-carboxylic acid (7s):

The reaction of 3-phenylpropylazide (604 mg, 3.75 mmol), propiolic acid (224 mg, 3.2 mmol), CuSO_4 (25.6 mg, 0.16 mmol, 5 mol%) and sodium ascorbate (63 mg, 0.32 mmol, 10 mol%) in *t*-BuOH/ H_2O (10 mL/10 mL) afforded the title acid (631 mg, 85% yield) as a white solid. ^1H NMR (400 MHz, DMSO- d_6) δ 13.06 (bs, 1 H), 8.74 (s, 1 H), 7.33-7.26 (m, 2 H), 7.24-7.16 (m, 3 H), 4.42 (t, J = 7.2 Hz, 2 H), 2.57 (t, J = 7.2 Hz, 2 H), 2.17 (pent, J = 7.2 Hz, 2 H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 161.7, 140.6, 128.8, 128.4, 128.3, 126.0, 49.2, 31.8, 31.0; HRMS (TOF-ESI) calcd for $\text{C}_{12}\text{H}_{14}\text{N}_3\text{O}_2[\text{M}+\text{H}]^+$: 232.1086, found: 232.1075.




1-(2-Chloro-4-methylbenzyl)-1H-1,2,3-triazole-4-carboxylic acid (7t): To a solution of 2-chloro-4-methylbenzyl alcohol (4 mmol, 626 mg) in dry DCM (10 mL) was added PBr_3 (mL, 4.4 mmol) dropwise at 0°C . The solution was stirred for 30 min at 0°C and quenched with NaHCO_3 solution. The organic phase was separated and the aqueous phase extracted with DCM (10 mL \times 3). The combined organic phase was washed with brine, dried over Na_2SO_4 and evaporated to dryness. The residue was dissolved in dry DMSO (10 mL), treated with NaN_3 (390 mg, 6 mmol) and the mixture was stirred at 50°C overnight. Then the reaction mixture was poured into water, extracted with ether (15 mL \times 3), dried over Na_2SO_4 and evaporated to get the azide (283 mg). The azide was then dissolved in *t*-BuOH (8 mL) and to the solution was added CuSO_4 (13 mg, 0.078 mmol), sodium ascorbate (31 mg, 0.156 mmol), H_2O (8 mL) and propiolic acid (109 mg, 1.56 mmol) and the mixture was sealed and stirred at room temperature overnight. The resulting suspension was poured into NaHCO_3 solution, and extracted with ether (15 mL \times 2) and the ethereal solution was discarded. The aqueous phase was acidified with 1N H_2SO_4 and extracted with EtOAc (15 mL \times 3), and the combined organic phase dried over Na_2SO_4 and evaporated to dryness to obtain the final acid (217 mg, 55% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.13 (bs, 1 H), 8.69 (s, 1 H), 7.36 (s, 1 H), 7.20 (s, 2 H), 5.71 (s, 2 H), 2.30 (s, 3 H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 161.6, 140.5, 139.6, 132.4, 130.6, 129.9, 129.7, 129.3, 128.4, 50.6, 20.3; HRMS (TOF-ESI) calcd for $\text{C}_{11}\text{H}_{10}\text{ClN}_3\text{O}_2\text{Na}[\text{M}+\text{Na}]^+$: 274.0359, found: 274.0354.

General procedure for the amide coupling reaction:




***N*-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1-phenyl-1H-1,2,3-triazole-4-carboxamide (4a):** to a solution of the triazole acid (0.13 mmol) in dry DCM (3 mL) was added sequentially $(\text{COCl})_2$ (0.40 mmol) and DMF (5 μL) under Ar and the resulting solution was stirred at room temperature overnight. Then the solvent was removed *in vacuo* and the residue was put on the high vacuum for 30 min. To another oven-dried RBF was added the amine (0.067 mmol), dry DCM (3 mL) and pyridine (0.6 mmol). To the above solution was added a solution of the acid chloride in dry DCM (4 mL) via a syringe dropwise. After addition the solution was stirred at room temperature overnight. Then the mixture was directly loaded on a silica gel column and eluted with 5% MeOH in DCM to afford the title product (13 mg, 43% yield). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 9.64 (s, 1 H), 9.59 (s, 1 H), 8.65 (s, 1 H), 8.06-8.01 (m, 2 H), 7.68-7.62 (m, 3 H), 7.60-7.54 (m, 1 H), 7.20-7.15 (m, 1 H), 4.80-4.60 (m, 1 H), 3.05-2.80

(m, 2 H), 2.60-2.40 (m, 2 H), 2.70 (s, 3 H), 2.12-1.98 (m, 2 H), 1.94-1.74 (m, 2 H); One methyl group overlays with solvent residue peaks. ^{13}C NMR (125 MHz, DMSO- d_6) δ 158.2, 157.9, 156.4, 149.2, 142.5, 136.1, 130.0, 129.4, 126.2, 125.6, 125.1, 120.8, 120.6, 113.6, 112.8, 110.8, 51.1, 44.4, 29.0, 8.2; HRMS (TOF-ESI) calcd for $\text{C}_{25}\text{H}_{26}\text{N}_5\text{O}_4[\text{M}+\text{H}]^+$: 460.1985, found: 460.1971.




1-Benzyl-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4b): Following the general procedure, the title compound was obtained as a white solid (15 mg, 47% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.65

(s, 1 H), 8.69 (s, 1 H), 8.05 (s, 1 H), 7.50-7.22 (m, 6 H), 6.90-6.83 (m, 1 H), 5.62 (s, 2 H), 4.48 (bs, 1 H), 2.74-2.56 (m, 2 H), 2.50-2.24 (m, 8 H), 2.12-1.98 (m, 2 H), 1.98-1.83 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.71, 158.68, 157.0, 149.7, 143.1, 133.6, 129.3, 129.2, 128.3, 125.6, 125.4, 124.7, 121.0, 115.3, 113.1, 110.3, 72.3, 54.6, 52.2, 46.2, 30.7, 8.3; HRMS (TOF-ESI) calcd for $\text{C}_{26}\text{H}_{28}\text{N}_5\text{O}_4[\text{M}+\text{H}]^+$: 474.2152; found: 474.2141.




1-(4-chlorophenyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4c):

Following the general procedure, the title compound was obtained as light yellow solid (19 mg, 58% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.71 (s, 1 H), 8.76 (s, 1 H), 8.58 (s, 1 H), 7.82-7.73 (m, 2 H), 7.63-7.54 (m, 2 H), 7.35 (d, $J = 8.4$ Hz, 1 H), 6.89 (d, $J = 8.4$ Hz, 1 H), 4.56-4.46 (m, 1 H), 2.78-2.63 (m, 2 H), 2.55-2.40 (m, 2 H), 2.38 (s, 3 H), 2.37 (s, 3 H), 2.16-2.03 (m, 2 H), 2.02-1.89 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3 with minor CD_3OD) δ 158.7, 158.4, 156.8, 149.5, 143.0, 135.3, 134.6, 130.0, 125.6, 125.3, 124.0, 121.8, 120.6, 115.0, 112.9, 110.1, 70.8, 51.4, 45.4, 29.4, 29.1, 8.0; HRMS (TOF-ESI) calcd for $\text{C}_{25}\text{H}_{25}\text{ClN}_5\text{O}_4[\text{M}+\text{H}]^+$: 494.1595; found: 494.1614.



1-(4-Bromophenyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4d):


Following the general procedure, title compound was obtained as light yellow solid (23 mg, 72% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.71 (s, 1 H), 8.77 (s, 1 H), 8.58 (s, 1 H), 7.78-7.67 (m, 3 H), 7.36 (d, $J = 8.4$ Hz, 1 H), 6.90 (d, $J = 8.4$ Hz, 1 H), 4.63-4.42 (m, 1 H), 2.84-2.70 (m, 2 H), 2.55-2.40 (m, 2 H), 2.43 (s, 3 H), 2.38 (s, 3 H), 2.15 (m, 2 H), 2.00 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.7, 157.4, 148.8, 142.6, 134.3, 131.2, 124.7, 123.9, 122.6, 122.5, 121.2, 120.1, 114.3, 112.2, 109.2, 50.8, 44.7, 29.0, 7.4; HRMS (TOF-ESI) calcd for $\text{C}_{25}\text{H}_{25}^{79}\text{BrN}_5\text{O}_4[\text{M}+\text{H}]^+$: 538.1090; found: 538.1089.




1-(4-methylphenyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4e):

Following the general procedure, the title compound was obtained as a white solid (17 mg, 53% yield). ^1H NMR (400 MHz, CDCl_3)


δ 9.71 (s, 1 H), 8.75 (s, 1 H), 8.55 (s, 1 H), 7.64-7.70 (m, 2 H), 7.41-7.36 (m, 2 H), 7.34 (d, J = 8.8 Hz, 1 H), 6.89 (d, J = 8.8 Hz, 1 H), 4.54-4.41 (m, 1 H), 2.75-2.58 (m, 2 H), 2.46 (s, 3 H), 2.44-2.31 (m, 8 H), 2.10-1.99 (m, 2 H), 1.99-1.87 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.7, 158.6, 157.1, 149.7, 143.2, 139.8, 134.1, 130.4, 125.5, 124.8, 123.7, 121.0, 120.6, 115.3, 113.0, 110.3, 52.3, 46.2, 30.7, 21.1, 8.3; HRMS (TOF-ESI) calcd for $\text{C}_{26}\text{H}_{28}\text{N}_5\text{O}_4[\text{M}+\text{H}]^+$: 474.2141; found: 474.2143.




1-(3-Chlorophenyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4f): following the general procedure, the title compound was obtained as an off-white solid (20 mg, 67% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.69 (s, 1 H), 8.75 (s, 1 H), 8.60 (s, 1 H), 7.86 (s, 1 H), 7.75-7.66 (m, 1 H), 7.60-7.51 (m, 2 H), 7.34 (d, J = 8.4 Hz, 1 H), 6.89 (d, J = 8.4 Hz, 1 H), 4.55-4.42 (m, 1 H), 2.78-2.60 (m, 2 H), 2.5-2.36 (m, 2 H), 2.36 (s, 6 H), 2.15-2.00 (m, 2 H), 2.00-1.80 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.1, 157.7, 156.7, 149.2, 142.6, 137.1, 134.2, 131.6, 129.2, 126.2, 125.8, 125.3, 120.6, 120.4, 119.2, 113.5, 112.6, 110.9, 71.8, 51.7, 45.6, 30.1, 8.1; HRMS (TOF-ESI) calcd for $\text{C}_{25}\text{H}_{25}^{35}\text{ClN}_5\text{O}_4[\text{M}+\text{H}]^+$: 494.1595; found: 494.1584.



1-(4-Chlorobenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4g): Following the general procedure, the 4-chlorobenzyl analogue was obtained as a white solid (24 mg, 79% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.65 (s, 1 H), 8.71 (s, 1 H), 8.06 (s, 1 H), 7.43-7.39 (m, 2 H), 7.33 (d, J = 8.4 Hz, 1 H), 7.30-7.25 (m, 2 H), 6.88 (d, J = 8.4 Hz, 1 H), 5.60 (s, 2 H), 4.60-4.48 (m, 1 H), 2.85-2.66 (m, 2 H), 2.65-2.55 (m, 2 H), 2.42 (s, 3 H), 2.36 (s, 3 H), 2.23-2.08 (m, 2 H), 2.05-1.92 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.8, 158.6, 156.9, 149.8, 143.3, 135.4, 132.2, 129.6, 125.6, 124.8, 121.1, 115.3, 113.2, 110.3, 53.9, 51.9, 46.0, 31.0, 30.2, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{26}\text{H}_{27}\text{ClN}_5\text{O}_4[\text{M}+\text{H}]^+$: 508.1752; found: 508.1740.




1-(4-Bromobenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4h): Following the general procedure, the 4-bromobenzyl analogue was obtained as a white solid (24 mg, 73% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.65 (s, 1 H), 8.70 (s, 1 H), 8.07 (s, 1 H), 7.60-7.54 (m, 2 H), 7.33 (d, J = 8.4 Hz, 1 H), 7.24-7.19 (m, 2 H), 6.88 (d, J = 8.4 Hz, 1 H), 5.58 (s, 2 H), 4.51 (bs, 1 H), 2.80-2.61 (m, 2 H), 2.55-2.40 (m, 2 H), 2.37 (s, 3 H), 2.36 (s, 3 H), 2.14-2.02 (m, 2 H), 2.01-1.88 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.7, 158.6, 157.0, 149.7, 143.3, 132.7, 132.5, 129.8, 125.6, 125.5, 124.9, 123.4, 121.0, 115.3, 113.1, 110.3, 53.9, 52.1, 46.1, 30.9, 30.5, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{26}\text{H}_{27}^{79}\text{BrN}_5\text{O}_4[\text{M}+\text{H}]^+$: 552.1246; found: 552.1235.




1-(4-Methylbenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4i): Following the general procedure, the 4-methylbenzyl analogue was obtained as a white solid (17 mg, 59% yield).

^1H NMR (400 MHz, CDCl_3) δ 9.65 (s, 1 H), 8.70 (s, 1 H), 8.02 (s, 1 H), 7.33 (d, $J = 8.8$ Hz, 1 H), 7.23 (s, 4 H), 6.87 (d, $J = 8.8$ Hz, 1 H), 5.57 (s, 2 H), 4.56 (bs, 1 H), 2.82-2.70 (m, 2 H), 2.70-2.52 (m, 2 H), 2.45 (bs, 3 H), 2.39 (s, 3 H), 2.36 (s, 3 H), 2.26-2.11 (m, 2 H), 2.08-1.93 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.8, 158.7, 156.7, 149.7, 143.0, 139.2, 130.6, 130.0, 128.4, 125.5, 124.6, 121.2, 115.2, 113.3, 110.2, 54.5, 51.8, 45.8, 30.9, 30.0, 21.2, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{27}\text{H}_{30}\text{N}_5\text{O}_4[\text{M}+\text{H}]^+$: 488.2298; found: 488.2293.




1-(4-Methoxybenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4j): Following the general procedure, the 4-methoxybenzyl analogue was obtained as a white solid (20 mg, 67% yield).

^1H NMR (400 MHz, CDCl_3) δ 9.64 (s, 1 H), 8.70 (s, 1 H), 8.01 (s, 1 H), 7.35-7.28 (m, 2 H), 6.97-6.92 (m, 2 H), 6.87 (d, $J = 8.4$ Hz, 1 H), 5.55 (s, 2 H), 4.53 (bs, 1 H), 3.84 (s, 3 H), 2.82-2.67 (m, 2 H), 2.65-2.45 (m, 2 H), 2.41 (bs, 3 H), 2.35 (s, 3 H), 2.19-2.07 (m, 2 H), 2.04-1.90 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 160.2, 158.8, 158.7, 156.8, 149.7, 143.0, 129.9, 125.5, 125.4, 124.7, 121.2, 115.3, 114.7, 113.2, 110.3, 55.4, 54.2, 51.9, 45.9, 30.9, 30.2, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{27}\text{H}_{30}\text{N}_5\text{O}_5[\text{M}+\text{H}]^+$: 504.2247; found: 504.2249.



1-(4-tert-Butylbenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4k): Following the general procedure, the title compound was obtained as a white solid (25 mg, 71% yield).


^1H NMR (400 MHz, CDCl_3) δ 9.63 (s, 1 H), 8.68 (s, 1 H), 8.01 (s, 1 H), 7.45-7.39 (m, 2 H), 7.33-7.28 (m, 1 H), 7.28-7.23 (m, 1 H), 6.85 (d, $J = 8.4$ Hz, 1 H), 5.56 (s, 2 H), 2.80-2.60 (m, 2 H), 2.55-2.35 (m, 2 H), 2.36 (s, 3 H), 2.34 (s, 3 H), 2.16-2.00 (m, 2 H), 2.00-1.87 (m, 2 H), 1.32 (s, 9 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.8, 158.7, 156.9, 152.5, 149.7, 143.0, 130.5, 128.2, 126.3, 125.6, 125.5, 124.7, 121.1, 115.3, 113.2, 110.3, 54.4, 52.0, 46.1, 34.7, 31.2, 30.5, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{30}\text{H}_{36}\text{N}_5\text{O}_4[\text{M}+\text{H}]^+$: 530.2767; found: 530.2773.



1-(4-Nitrobenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4l):


Following the general procedure, the title compound was obtained as a yellow solid (17 mg, 55% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.65 (s, 1 H), 8.69 (s, 1 H), 8.27 (d, $J = 8.4$ Hz, 2 H), 8.20 (s, 1 H), 7.48 (d, $J = 8.4$ Hz, 2 H), 7.34

(d, $J = 8.4$ Hz, 1 H), 6.86 (d, $J = 8.4$ Hz, 1 H), 5.75 (s, 2 H), 4.73 (bs, 1 H), 3.20-2.93 (m, 2 H), 2.80-2.60 (m, 2 H), 2.60-2.40 (m, 2 H), 2.35 (s, 3 H), 2.23-2.10 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.5, 158.4, 156.0, 149.7, 148.3, 143.5, 140.6, 128.5, 126.0, 125.9, 124.54, 124.50, 121.4, 115.0, 113.6, 109.9, 53.6, 50.0, 44.5, 29.7, 28.0, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{26}\text{H}_{27}\text{N}_6\text{O}_6[\text{M}+\text{H}]^+$: 519.1992; found: 519.2000.




1-(4-Fluorobenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4m): Following the general procedure, the title compound was obtained as a white solid (19 mg, 58% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.61 (s, 1 H), 8.66 (s, 1

H), 8.04 (s, 1 H), 7.36-7.28 (m, 3 H), 7.13-7.05 (m, 2 H), 6.84 (d, $J = 8.4$ Hz, 1 H), 5.57 (s, 2 H), 4.51-4.40 (m, 1 H), 2.75-2.57 (m, 2 H), 2.50-2.35 (m, 2 H), 2.33 (s, 3 H), 2.32 (s, 3 H), 2.10-1.97 (m, 2 H), 1.96-1.85 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 164.0, 162.0, 158.6, 157.9 (d, $J_{\text{C-F}} = 211.3$ Hz), 149.7, 143.2, 130.23, 130.17, 129.5 (d, $J_{\text{C-F}} = 3.6$ Hz), 125.5 (d, $J_{\text{C-F}} = 5.5$ Hz), 124.8, 121.0, 116.4, 116.3, 115.3, 113.0, 110.3, 53.8, 52.2, 46.1, 30.6, 29.6, 8.3; ^{19}F NMR (MHz, CDCl_3) δ (-111.6)-(-111.9); HRMS (TOF-ESI) calcd for $\text{C}_{26}\text{H}_{27}\text{FN}_5\text{O}_4[\text{M}+\text{H}]^+$: 492.2047; found: 492.2035.




1-(3-Chlorobenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4n): Following the general procedure, the 3-chlorobenzyl analogue was obtained as a white solid (15 mg, 44% yield).

^1H NMR (400 MHz, CDCl_3) δ 9.65 (s, 1 H), 8.70 (s, 1 H), 8.09 (s, 1 H), 7.42-7.30 (m, 4 H), 7.23-7.19 (m, 1 H), 6.90-6.85 (d, $J = 8.4$ Hz, 1 H), 5.60 (s, 2 H), 4.56-4.44 (m, 1 H), 2.75-2.62 (m, 2 H), 2.50-2.35 (m, 2 H), 2.36 (s, 6 H), 2.18-2.00 (m, 2 H), 2.00-1.87 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.7, 158.5, 157.1, 149.7, 143.3, 135.5, 135.3, 130.6, 129.4, 128.3, 126.2, 125.7, 125.5, 124.9, 121.0, 115.3, 113.1, 110.3, 72.1, 53.9, 52.2, 46.2, 30.6, 29.7, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{26}\text{H}_{27}\text{ClN}_5\text{O}_4[\text{M}+\text{H}]^+$: 508.1752, found: 508.1749.




1-(3-Methoxybenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (4o): Following the general procedure, the title compound was obtained as a light yellow solid (21 mg, 62% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.63 (s, 1 H), 8.68 (s, 1 H), 8.04

(s, 1 H), 7.35-7.29 (m, 2 H), 6.95-6.80 (m, 4 H), 5.56 (s, 2 H), 4.54 (bs, 1 H), 3.80 (s, 3 H), 2.85-2.70 (m, 2 H), 2.70-2.50 (m, 2 H), 2.43 (s, 3 H), 2.34 (s, 3 H), 2.25-2.05 (m, 2 H), 2.05-1.90 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 160.2, 158.73, 158.68, 158.67, 149.7, 143.1, 135.0, 134.0, 125.7, 125.6, 124.6, 121.2, 120.4, 115.2, 114.6, 113.9, 113.3, 110.2, 53.3, 54.6, 51.7, 45.7, 29.8, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{27}\text{H}_{30}\text{N}_5\text{O}_5[\text{M}+\text{H}]^+$: 504.2247; found: 504.2242.




1-(2-Chlorobenzyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (**4p**):

Following the general procedure, the 2-chlorobenzyl analogue was obtained as a white solid (30 mg, 98% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.66 (s, 1 H), 8.71 (s, 1 H), 8.15 (s, 1 H), 7.51-7.47 (m, 1 H), 7.42-7.35 (m, 1 H), 7.35-7.31 (m, 3 H), 6.88 (d, J = 8.4 Hz, 1 H), 5.76 (s, 2 H), 4.53 (bs, 1 H), 2.80-2.68 (m, 2 H), 2.62-2.46 (m, 2 H), 2.42 (bs, 3 H), 2.36 (s, 3 H), 2.22-2.06 (m, 2 H), 2.04-1.90 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.7, 156.8, 149.7, 143.0, 133.8, 131.5, 130.79, 130.77, 130.2, 127.8, 125.9, 125.5, 124.7, 121.1, 115.3, 113.2, 110.3, 52.0 (two peaks overlapped), 45.9, 30.9, 30.2, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{26}\text{H}_{27}\text{ClN}_5\text{O}_4[\text{M}+\text{H}]^+$: 508.1752; found: 508.1739.




1-(Cyclohexylmethyl)-N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1H-1,2,3-triazole-4-carboxamide (**4q**):

Following the general procedure, the title compound was obtained as an off-white solid (25 mg, 78% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.66 (s, 1 H), 8.73 (s, 1 H), 8.11 (s, 1 H), 7.34 (d, J = 8.4 Hz, 1 H), 6.88 (d, J = 8.4 Hz, 1 H), 4.58-4.46 (m, 1 H), 4.29 (d, J = 7.2 Hz, 1 H), 2.78-2.66 (m, 2 H), 2.58-2.42 (m, 2 H), 2.40 (s, 3 H), 2.36 (s, 3 H), 2.20-2.05 (m, 2 H), 2.05-1.86 (m, 3 H), 1.85-1.60 (m, 5 H), 1.35-1.15 (m, 3 H), 1.12-0.97 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 159.0, 158.7, 156.9, 149.7, 142.6, 126.0, 125.5, 124.7, 121.2, 115.3, 113.2, 110.3, 56.9, 52.0, 46.0, 38.7, 30.4, 25.9, 25.4, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{26}\text{H}_{33}\text{N}_5\text{O}_4\text{Na}[\text{M}+\text{Na}]^+$: 502.2430; found: 502.2425.



N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1-phenethyl-1H-1,2,3-triazole-4-carboxamide (**4r**):


Following the general procedure, the title compound **4r** was obtained as a light yellow solid (10 mg, 30% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.64 (s, 1 H), 8.70 (s, 1 H), 7.85 (s, 1 H), 7.36-7.25 (m, 4 H), 7.15-7.09 (m, 2 H), 6.90-6.85 (m, 1 H), 4.70 (t, J = 7.2 Hz, 2 H), 4.55-4.40 (m, 1 H), 3.28 (t, J = 7.2 Hz, 2 H), 2.76-2.60 (m, 2 H), 2.50-2.35 (m, 2 H), 2.36 (s, 6 H), 2.12-2.00 (m, 2 H), 1.98-1.86 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.75, 158.74, 157.0, 149.7, 142.5, 136.3, 129.0, 128.6, 127.4, 125.9, 125.4, 124.7, 121.1, 115.3, 113.1, 110.3, 72.2 (b), 52.3 (b), 52.1, 46.2, 36.5, 30.7, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{27}\text{H}_{30}\text{N}_5\text{O}_4[\text{M}+\text{H}]^+$: 488.2298; found: 488.2298.




N-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole-4-carboxamide (**4s**):

following the general procedure, the title compound was obtained as a white solid (14 mg, 41% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.66 (s, 1 H), 8.73 (s, 1 H), 8.12 (s, 1 H), 7.37-7.31 (m, 1 H), 7.28-7.22 (m, 1 H), 7.22-7.18 (m, 2 H), 6.90-6.85 (m, 1 H), 4.62-4.52 (m, 1 H), 4.46 (t, J = 7.2 Hz, 2 H), 2.90-2.75 (m, 2 H), 2.71 (t, J = 7.2 Hz, 2 H), 2.68-2.52 (m, 2 H), 2.46


(s, 3 H), 2.63 (s, 3 H), 2.34 (pent, $J = 7.2$ Hz, 2 H), 2.28-2.12 (m, 2 H), 2.08-1.95 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.9, 158.7, 156.7, 149.8, 142.8, 139.7, 128.8, 128.5, 126.6, 125.7, 125.6, 124.7, 121.3, 115.3, 113.4, 110.2, 51.7, 50.0, 45.7, 32.4, 31.5, 29.9, 8.4; HRMS (TOF-ESI) calcd for $\text{C}_{28}\text{H}_{32}\text{N}_5\text{O}_4[\text{M}+\text{H}]^+$: 502.2454; found: 502.2436.




N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1-phenyl-1H-1,2,3-triazole-4-carboxamide (**5a**): Following the general procedure, the title compound was obtained as a white solid (21 mg, 70% yield). ^1H NMR (400 MHz, CDCl_3) δ 9.07 (s, 1 H), 8.64 (s, 1 H), 7.84-7.77 (m, 4 H), 7.64-7.57 (m, 4 H), 7.57-7.50 (m, 3 H), 7.02-6.98 (m, 2 H), 4.43-4.33 (m, 1 H), 2.80-2.65 (m, 2 H), 2.38-2.25 (m, 5 H), 2.11-2.00 (m, 2 H), 1.97-1.82 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.8, 156.6, 143.8, 137.1, 136.3, 135.9, 133.1, 129.9, 129.5, 127.8, 127.1, 124.2, 120.7, 120.3, 116.3, 71.3, 52.2, 45.8, 30.2; HRMS (TOF-ESI) calcd for $\text{C}_{27}\text{H}_{28}\text{N}_5\text{O}_2[\text{M}+\text{H}]^+$: 454.2243; found: 454.2238.




1-Benzyl-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (**5b**): Following the general procedure, the benzyl analogue was obtained as a white solid (17 mg, 55% yield). ^1H NMR (400 MHz, CDCl_3) δ 8.99 (s, 1 H), 8.08 (s, 1 H), 7.76-7.72 (m, 2 H), 7.60-7.50 (m, 4 H), 7.46-7.40 (m, 3 H), 7.36-7.31 (m, 2 H), 7.03-6.97 (m, 2 H), 5.62 (s, 2 H), 4.44-4.33 (1 H), 2.80-2.65 (m, 2 H), 2.40-2.22 (m, 5 H), 2.10-1.98 (m, 2 H), 1.97-1.82 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.7, 156.9, 143.8, 137.0, 136.1, 133.6, 133.1, 129.4, 129.2, 128.3, 127.9, 127.2, 125.7, 120.1, 116.3, 72.1, 54.7, 52.7, 46.2, 30.9; HRMS (TOF-ESI) calcd for $\text{C}_{28}\text{H}_{30}\text{N}_5\text{O}_2[\text{M}+\text{H}]^+$: 468.2400; found: 468.2407.




N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1-phenethyl-1H-1,2,3-triazole-4-carboxamide (**5c**): Following the general procedure, the title compound was obtained as a white solid (18 mg, 56% yield). ^1H NMR (400 MHz, CDCl_3) δ 8.99 (s, 1 H), 7.92 (s, 1 H), 7.78-7.73 (m, 2 H), 7.60-7.50 (m, 4 H), 7.37-7.26 (m, 3 H), 7.16-7.11 (m, 2 H), 7.02-6.98 (m, 2 H), 4.70 (t, $J = 7.2$ Hz, 2 H), 4.48-4.40 (m, 1 H), 3.28 (t, $J = 7.2$ Hz, 2 H), 2.90-2.74 (m, 2 H), 2.60-2.45 (m, 2 H), 2.40 (s, 3 H), 2.17-2.06 (m, 2 H), 2.01-1.89 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.7, 156.7, 143.2, 136.9, 136.3, 136.2, 133.3, 129.0, 128.6, 127.9, 127.4, 127.2, 125.9, 120.1, 116.3, 52.1, 51.9, 45.6, 36.5, 30.1, 22.6; HRMS (TOF-ESI) calcd for $\text{C}_{29}\text{H}_{32}\text{N}_5\text{O}_2[\text{M}+\text{H}]^+$: 482.2556; found: 482.2556.




1-(4-Chlorobenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5d): Following the general procedure, the 4-chlorobenzyl analogue was obtained (12 mg, 35% yield) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.17 (s, 1 H), 7.74-7.66 (m, 2 H), 7.56-7.44 (m, 4 H), 7.39-7.32 (m, 2 H), 7.27-7.22 (m, 2 H), 6.98-6.90 (m, 2 H), 5.55 (s, 2 H), 4.44-4.32 (m, 1 H), 2.79-2.61 (m, 2 H), 2.43-2.25 (m, 5 H), 2.10-1.95 (m, 2 H), 1.95-1.80 (m, 2 H); ^{13}C NMR (125 MHz, CD_3OD with minor CDCl_3 , ref CDCl_3) δ 156.2, 154.5, 141.2, 135.4, 133.2, 132.6, 131.1, 130.2, 128.0, 126.9, 125.6, 125.5, 124.2, 118.7, 114.2, 50.4, 43.7, 28.5; HRMS (TOF-ESI) calcd for $\text{C}_{28}\text{H}_{29}\text{ClN}_5\text{O}_2[\text{M}+\text{H}]^+$: 502.2010, found: 502.2006.



1-(4-Bromobenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5e): Following the general procedure, the 4-bromobenzyl analogue was obtained as a white solid (21 mg, 57% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.53 (s, 1 H), 8.85 (s, 1 H), 7.91-7.86 (m, 2 H), 7.65-7.55 (m, 6 H), 7.37-7.32 (m, 2 H), 7.06-7.00 (m, 2 H), 5.70 (s, 2 H), 4.43 (bs, 1 H), 2.80-2.62 (m, 2 H), 2.37-2.15 (m, 5 H), 2.02-1.91 (m, 2 H), 1.74-1.62 (m, 2 H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 158.2, 156.4, 143.1, 137.3, 135.2, 135.0, 132.2, 131.8, 130.3, 127.6, 127.4, 126.2, 121.6, 120.7, 116.2, 71.6, 52.4, 52.2, 45.5, 30.3; HRMS (TOF-ESI) calcd for $\text{C}_{28}\text{H}_{29}^{79}\text{BrN}_5\text{O}_2[\text{M}+\text{H}]^+$: 546.1505, found: 546.1494.




1-(4-Methylbenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5f): Following the general procedure, the 4-methylbenzyl analogue was obtained (20 mg, 63% yield) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 9.01 (s, 1 H), 7.77-7.72 (m, 2 H), 7.59-7.50 (m, 4 H), 7.23 (s, 4 H), 7.01-6.97 (m, 2 H), 5.56 (s, 2 H), 4.43 (bs, 1 H), 2.86-2.73 (m, 2 H), 2.60-2.42 (m, 2 H), 2.40 (s, 3 H), 2.39 (s, 3 H), 2.17-2.05 (m, 2 H), 2.00-1.87 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.2, 156.4, 143.0, 137.7, 137.4, 135.1, 132.6, 132.0, 129.4, 128.1, 127.4, 127.3, 126.2, 120.7, 116.2, 71.4, 53.0, 52.1, 45.3, 30.1, 20.7; HRMS (TOF-ESI) calcd for $\text{C}_{29}\text{H}_{32}\text{N}_5\text{O}_2[\text{M}+\text{H}]^+$: 482.2556, found: 482.2545.




1-(4-Methoxybenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5g): Following the general procedure, the 4-methoxybenzyl analogue **5g** was obtained as an off-white solid (14 mg, 42% yield). ^1H NMR (400 MHz, CDCl_3) δ 8.97 (s, 1 H), 8.02 (s, 1 H), 7.75-7.69 (m, 2 H), 7.57-7.47 (m, 4 H), 7.29-7.27

(m, 1 H), 7.00-6.90 (m, 4 H), 5.52 (s, 2 H), 4.40 (bs, 1 H), 3.82 (s, 3 H), 2.82-2.70 (m, 2 H), 2.58-2.35 (m, 2 H), 2.37 (s, 3 H), 2.15-2.03 (m, 2 H), 1.97-1.85 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3 and minor CD_3OD) δ 160.1, 157.8, 156.5, 143.5, 136.9, 136.0, 133.3, 129.8, 127.9, 127.1, 125.7, 125.5, 120.1, 116.3, 114.6, 55.3, 54.2, 51.8, 45.5, 30.8; HRMS (TOF-ESI) calcd for $\text{C}_{29}\text{H}_{32}\text{N}_5\text{O}_3[\text{M}+\text{H}]^+$: 498.2505; found: 498.2499.




1-(4-tert-Butylbenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5h): Following the general procedure, the title compound was obtained as a white solid (16 mg, 46% yield). ^1H NMR (400 MHz, CDCl_3) δ 8.97 (s, 1 H), 8.03 (s, 1 H), 7.72 (d, J = 8.4 Hz, 2 H), 7.54 (d, J = 8.4 Hz, 2 H), 7.51 (d, J = 8.4 Hz, 2 H), 7.43 (d, J = 8.4 Hz, 2 H), 7.29-7.24 (m, 2 H), 6.97

(d, J = 8.4 Hz, 2 H), 5.56 (s, 2 H), 4.44 (bs, 1 H), 2.95-2.75 (m, 2 H), 2.45 (s, 3 H), 2.30-2.05 (m, 2 H), 2.05-1.90 (m, 2 H), 1.32 (s, 9 H); ^{13}C NMR (125 MHz, CD_3OD) δ 158.2, 156.2, 150.8, 143.1, 137.4, 135.1, 132.7, 127.8, 127.5, 127.3, 126.2, 125.6, 120.7, 116.3, 52.9, 34.3, 31.0, 30.7; HRMS (TOF-ESI) calcd for $\text{C}_{32}\text{H}_{38}\text{N}_5\text{O}_2[\text{M}+\text{H}]^+$: 524.3026; found: 524.3029.



1-(4-Nitrobenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5i): Following the general procedure the title compound was obtained as a yellow solid (20 mg, 59% yield). ^1H NMR (400 MHz, CDCl_3) δ 8.97 (s, 1 H), 8.27 (d, J = 8.4 Hz, 2 H), 8.18 (s, 2 H), 7.73 (d, J = 8.4 Hz, 1 H), 7.56 (d, J = 8.4 Hz, 2 H), 7.51 (d, J = 8.4 Hz, 2 H), 7.47 (d, J = 8.4 Hz, 2


H), 6.97 (d, J = 8.4 Hz, 2 H), 5.73 (s, 2 H), 4.48 (bs, 1 H), 2.95-2.80 (m, 2 H), 2.75-2.55 (m, 2 H), 2.47 (s, 3 H), 2.30-2.12 (m, 2 H), 2.10-1.86 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.3, 156.9, 148.4, 144.3, 140.6, 137.2, 136.0, 133.2, 128.8, 128.0, 127.3, 126.0, 124.6, 120.2, 116.4, 53.6, 53.5, 52.5, 46.0, 30.5; HRMS (TOF-ESI) calcd for $\text{C}_{28}\text{H}_{29}\text{N}_6\text{O}_4[\text{M}+\text{H}]^+$: 513.2250; found: 513.2270.




1-(4-Fluorobenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5j): Following the general procedure, the title compound was obtained as a white solid (17 mg, 53% yield). ^1H NMR (400 MHz, CDCl_3) δ 8.97 (s, 1 H), 8.10-8.06 (m, 1 H), 7.80-7.70 (m, 2 H), 7.60-7.49 (m, 4 H), 7.38-7.31 (m, 2 H), 7.18-7.08 (m, 2 H), 7.04-6.96 (m, 2 H),

5.59 (s, 2 H), 4.45-4.30 (m, 1 H), 2.81-2.68 (m, 2 H), 2.45-2.25 (m, 5 H), 2.13-2.00 (m, 2 H), 1.98-1.85 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.1 (d, $J_{\text{C-F}}$ = 247.4 Hz), 157.6, 156.9, 143.9, 137.1, 136.1, 133.1, 130.3 (d, $J_{\text{C-F}}$ = 8.1 Hz), 129.5 (d, $J_{\text{C-F}}$ = 2.5 Hz), 127.9,


127.3, 125.6, 120.2, 116.5, 116.4, 72.1, 54.0, 54.7, 46.2, 30.9; HRMS (TOF-ESI) calcd for $C_{28}H_{29}FN_5O_2[M+H]^+$: 486.2305; found: 486.2305.




1-(3-Chlorobenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5k): following the general procedure, the title compound was obtained as a white solid (12 mg, 36% yield). 1H NMR (400 MHz, $CDCl_3$) δ 8.98 (s, 1 H), 8.12 (s, 1 H), 7.79-7.70 (m, 2 H), 7.61-7.48 (m, 4 H), 7.43-7.30 (m, 3 H), 7.25-7.16 (m, 2 H), 7.04-6.96 (m, 2 H), 5.59 (s, 2 H), 4.45-4.30 (m, 1 H), 2.85-2.66 (m, 2 H), 2.45-2.24 (m, 5 H), 2.11-2.00 (m, 2 H), 1.96-1.83 (m, 2 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 157.5, 156.9, 144.0, 137.1, 136.0, 135.5, 135.3, 133.1, 130.6, 129.4, 128.3, 127.9, 127.2, 126.2, 125.7, 120.2, 116.3, 72.1, 53.9, 52.6, 46.2, 30.8; HRMS (TOF-ESI) calcd for $C_{28}H_{29}ClN_5O_2[M+H]^+$: 502.2010; found: 502.2005.




1-(3-Methoxybenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5l): Following the general procedure, the title compound was obtained as a white solid (14 mg, 42% yield). 1H NMR (400 MHz, $CDCl_3$ with MeOD) δ 8.12 (s, 1 H), 7.70-7.65 (m, 2 H), 7.51-7.43 (m, 4 H), 7.28-7.23 (m, 2 H), 6.94-6.88 (m, 2 H), 6.88-6.81 (m, 2 H), 6.79-6.76 (m, 1 H); 5.50 (s, 2 H), 4.62-4.50 (m, 1 H), 3.74 (s, 3 H), 3.10-2.94 (m, 2 H), 2.62 (s, 3 H), 2.36-2.18 (m, 2 H), 2.14-2.00 (m, 2 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 160.2, 157.7, 156.8, 143.7, 137.0, 136.1, 134.9, 133.2, 130.5, 127.9, 127.2, 125.7, 120.4, 120.1, 116.3, 114.5, 114.0, 71.9, 55.3, 54.6, 52.5, 46.1, 30.7; HRMS (TOF-ESI) calcd for $C_{29}H_{32}N_5O_3[M+Na]^+$: 498.2505, found: 498.2510.



1-(2-Chlorobenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5m): Following the general procedure, the 2-chlorobenzyl analogue 5m was obtained (12 mg, 35% yield) as a white solid. 1H NMR (400 MHz, $DMSO-d_6$) δ 10.54 (s, 1 H), 8.78 (s, 1 H), 7.89 (d, $J = 8.4$ Hz, 2 H), 7.62-7.50 (m, 5 H), 7.47-7.35 (m, 2 H), 7.34-7.25 (m, 1 H), 7.03 (d, $J = 8.4$ Hz, 2 H), 5.83 (s, 2 H), 4.44 (bs, 1 H), 2.80-2.62 (m, 2 H), 2.40-2.15 (m, 5 H), 2.05-1.90 (m, 2 H), 1.80-1.60 (m, 2 H); ^{13}C NMR (125 MHz, $DMSO-d_6$) δ 158.1, 156.4, 142.9, 137.3, 135.2, 132.9, 132.6, 132.2, 130.6, 130.4, 129.7, 127.8, 127.4, 126.2, 120.7, 116.2, 71.5, 52.2, 51.0, 45.5, 30.2; HRMS (TOF-ESI) calcd for $C_{28}H_{29}ClN_5O_2[M+H]^+$: 502.2010; found: 502.2008.



1-(2-Chloro-4-methylbenzyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5n): following the general procedure, the title compound was obtained as a white solid (17 mg, 49% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.98 (s, 1 H), 8.13 (s, 1 H), 7.78-7.72 (m, 2 H), 7.60-7.49 (m, 4 H), 7.32-7.30 (m, 1 H), 7.25-7.21 (m, 1 H), 7.16-7.10 (m, 1 H), 7.02-6.96 (m, 2 H), 5.70 (s, 2 H), 7.44-7.34 (m, 1 H), 2.85-2.67 (m, 2 H), 2.38 (s, 3 H), 2.35 (s, 3 H), 2.40-2.28 (m, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 157.7, 156.9, 143.5, 141.5, 137.0, 136.1, 133.7, 133.1, 130.71, 130.65, 128.5, 128.3, 127.9, 127.2, 125.8, 120.1, 116.3, 72.1, 52.6, 51.8, 46.2, 30.8, 21.0; HRMS (TOF-ESI) calcd for C₂₉H₃₁ClN₅O₂[M+H]⁺: 516.2166; found: 516.2160.



1-(Cyclohexylmethyl)-N-(4'-((1-methylpiperidin-4-yl)oxy)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazole-4-carboxamide (5o): Following the general procedure, the title compound was obtained as a white solid (19 mg, 59% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.98 (s, 1 H), 8.11 (s, 1 H), 7.74 (d, *J* = 8.8 Hz, 2 H), 7.56 (d, *J* = 8.4 Hz, 2 H), 7.51 (d, *J* = 8.4 Hz, 2 H), 6.98 (d, *J* = 8.8 Hz, 2 H), 4.50-4.34 (m, 1 H), 4.27 (d, *J* = 7.2 Hz, 2 H), 2.83-2.67 (m, 2 H), 2.48-2.30 (m, 5 H), 2.05-2.00 (m, 2 H), 2.00-1.80 (m, 2 H), 1.80-1.58 (m, 6 H), 1.34-1.10 (m, 4 H), 1.10-0.95 (m, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 157.9, 156.8, 143.3, 137.0, 136.2, 133.3, 127.9, 127.2, 126.0, 120.1, 116.3, 57.0, 52.2, 45.8, 38.7, 30.4, 26.0, 25.4; HRMS (TOF-ESI) calcd for C₂₈H₃₆N₅O₂[M+H]⁺: 474.2869; found: 474.2860.

MTS/PMS cell viability assay (SKBr3 and MCF-7 cells)

Cells were maintained in a 1:1 mixture of Advanced DMEM/F12 (Gibco) supplemented with non-essential amino acids, L-glutamine (2 mM), streptomycin (500 µg/mL), penicillin (100 units/mL), and 10% FBS. Cells were grown to confluence in a humidified atmosphere (37° C, 5% CO₂), seeded (2000/well, 100 µL) in 96-well plates, and allowed to attach overnight. Compound at varying concentrations in DMSO (1% DMSO final concentration) was added, and cells were returned to the incubator for 72 h. At 72 h, the number of viable cells was determined using an MTS/PMS cell proliferation kit (Promega) per the manufacturer's instructions. Cells incubated in 1% DMSO were used at 100% proliferation, and values were adjusted accordingly. IC₅₀ values were calculated from separate experiments performed in triplicate using GraphPad Prism.

Promega CellTiter-Glo (CTG) luminescent assay

Antiproliferative activities against MDA-MB-468LN, MDA1986 and JMAR cell lines were performed with 384-well white plates with the Promega CellTiter-Glo (CTG) luminescent assay with 72h compound treatment. Data analysis was performed using GraphPad Prism. Selected data were further checked with MTS/PMS cell viability assay with 96-well plates, which correlated well with Promega CellTiter-Glo luminescent assay (not reported).

Sulforhodamine B Assay

The sulforhodamine B assay is used to measure drug-induced cytotoxicity and cell proliferation for large-scale drug-screening applications. Its principle is based on the ability of the protein dye sulforhodamine B to bind electrostatically on pH dependent protein basic amino acid residues of trichloroacetic acid-fixed cells. The aim is to evaluate samples showing selective growth inhibition or cell killing of particular tumor cell lines.

The SRB assay is performed by treating cells using a 10 point dose-response curve. The cells are fixed with trichloroacetic acid solution and stained with sulforhodamine B dye. The stained cells are then solubilized with 10mM Tris buffer and read for absorbance at 565nm.

Percentage growth is calculated at each of the drug concentration levels using the absorbance raw data.

Percentage growth inhibition is calculated as:

$[(Ti - Tz)/(C-Tz)] \times 100$ for concentrations for which $Ti \geq Tz$

$[(Ti - Tz)/(Tz)] \times 100$ for concentrations for which $Ti < Tz$.

Ti = Absorbance of wells at a given drug concentration level.

Tz = Absorbance time zero wells

C = Absorbance of untreated wells (media and cells only)

After growth inhibition values have been calculated, the data is plotted on Graphpad Prism software. Data is entered and plotted on a sigmoidal dose-response curve using non-linear regression.

Western blot Analyses

MCF-7 cells were cultured as described above and treated with various concentrations of drug, GDA in DMSO (1% DMSO final concentration), or vehicle (DMSO) for 24 h. Cells were harvested in cold PBS and lysed in RIPA lysis buffer containing 1 mM PMSF, 2 mM sodium orthovanadate, and protease inhibitors on ice for 1 h. Lysates were clarified at 14000g for 10 min at 4° C. Protein concentrations were determined using the Pierce BCA protein assay kit per the manufacturer's instructions. Equal amounts of protein (15 µg) were electrophoresed under reducing conditions, transferred to a PVDF membrane, and immunoblotted with the corresponding specific antibodies. Membranes



were incubated with an appropriate horseradish peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and visualized.

Proteolytic Fingerprinting Assay



Rabbit reticulocyte (Green Hectares) incubated under conditions of protein synthesis at 30°C in the presence of compound or vehicle (1% DMSO) for 10 minutes. Each reaction mixture contained 66.6% rabbit reticulocyte and 33.3% ATP regenerating system (10 mM creatine phosphate and 20 $\mu\text{g mL}^{-1}$ creatine phosphokinase) and a final concentration of 75 mM KCl. Each reaction mixture contained the indicated amount of compound. After incubating, the samples were immediately placed on ice and the indicated amount of TPCCK-treated trypsin (Worthington) was added to each sample. The samples digested on ice for an additional 6 minutes and the reactions were quenched by the addition of Laemmli sample buffer followed by immediate boiling. Equal amounts of each sample were electrophoresed under reducing conditions (12% acrylamide gels), transferred to PVDF, and immunoblotted with an antibody specific to the Hsp90 C-terminus. Membranes were incubated with an appropriate horseradish peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and visualized.

References


1. Kolarovic, A.; Schnurch, M.; Mihovilovic, M. D., Tandem catalysis: from alkynoic acids and aryl iodides to 1,2,3-triazoles in one pot. *J. Org. Chem.* **2011**, 76 (8), 2613-8.






7g





7g












7i







7i


















































































































































5j



5j



5k



5k

